Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: heterocyclic hydrazone therapeutics - Vion

Drug Profile

Research programme: heterocyclic hydrazone therapeutics - Vion

Alternative Names: EPH 116; EPH 135; EPH 136; EPH 278; EPH 279; EPH 280; EPH 286; EPH 289; EPH 349; EPH 350; EPH 351; EPH 369; EPH 52

Latest Information Update: 13 Jul 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Austria Wirtschaftsservice; University of Innsbruck
  • Developer Vion Pharmaceuticals
  • Class Heterocyclic compounds; Hydrazones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 13 Jul 2009 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 30 Apr 2007 Preclinical development is ongoing in USA
  • 26 Apr 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the Cancer pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top